



STAMFORD
PHARMACEUTICALS INC

Media Release

Monday, 8 May 2023

Stamford Pharmaceuticals Inc has relocated its head office to Austin Texas.

Monday 8 May 2023

Stamford Pharmaceuticals Inc, a clinical stage oncology company with a near-term pipeline focused on cutaneous cancer announced today that it has relocated its head office to Austin Texas to Suite 1900, 500 W, 2ND St. Stamford Pharmaceuticals is currently undertaking a Phase 2 clinical trial evaluating its lead agent SP-002 as a treatment for patients that present with multiple basal cell carcinomas. The study is on-going and is expected to complete in the 1H of 2023. The Company will also commence a second study, a Phase 2b in Locally Advanced Basal Cell Carcinoma in 2H, 2023.

-ENDS-

For more information, please contact:

Clement Leong
Chief Executive Officer
Stamford Pharmaceuticals Inc
500 W, 2ND ST, Suite 1900
Austin, TX 78701-4687
Mobile US: +1 512-694-4241
Mobile Australia: +61 421-837-218
Email:
clementleong@stamfordpharmaceuticals.com
Web: <http://stamfordpharmaceuticals.com/>

About Stamford Pharmaceuticals and Ascend Biopharmaceuticals

Stamford Pharmaceuticals Inc is a clinical-stage oncology focused company development treatments for cutaneous and visceral cancers.

For more information, please visit www.stamfordpharmaceuticals.com.